
Faster, simpler, differential diagnosis
There is a clear need for improved technology solutions in diagnosis

Non-Invasive
The NeuroMotor Pen is a unique, non-invasive, patented medical device that supports an earlier and more accurate diagnosis and offers monitoring of neuromotor impairments.

Sensor Technologies
The NeuroMotor Pen, with built-in highly accurate sensor technologies, combined with its analytical software, processes minute limb and hand motion parameters to quantify fine motor skills, represented by ‘motion features’.

Additional Clinical Information
These motion features are clinically validated biomarkers and provide objective information to clinicians about movement abnormalities, to support differential diagnosis and clinical management of Parkinson's disease and other neuromotor impairments.

Streamlining Neuromotor Services
The NeuroMotor Pen is an innovative technology for use in triage to support general practitioners to make a more accurate assessment before referral to neuromotor specialists services to increase the efficiency of specialist services and reduce costs.
Investors







Accurately Assessing Fine Motor Skills
There are many symptoms of Parkinson’s disease. However, minor changes of fine motor control of the fingers, leading to bradykinesia – slowness of motion – micrographia – small handwriting – as well as tremors are often early indicators of Parkinson's disease.
Initially, these symptoms can be very subtle and hardly noticeable. Our clinical trials and over 10 years of research have demonstrated that the NeuroMotor Pen is capable of detecting these early signs with high accuracy.
Using information gathered from a set of standardised handwriting and drawing tasks, the NeuroMotor Pen provides an accurate and objective patient assessment to clinicians, offering an earlier, non-invasive diagnostic of Parkinson’s disease.
People with Parkinson's disease have a hard time controlling movement due to the neurodegeneration in parts of the brain, which can make fine motor skills like writing more difficult. Early detection and treatment improve general patient outcomes and the chance of maintaining good motor function.
Make a Difference Today
Manus Neurodynamica is revolutionising neuromotor health care management by using their patented technology and unique diagnostic algorithms to record validated biomarkers of neuromotor impairments and differentiate between movements, to radically improve patient diagnosis and disease management.
As side effects of antipsychotic medications lead to Parkinsonism – symptoms that mimic the movement abnormalities in Parkinson’s, Manus Neurodynamica has been investigating the use of the NeuroMotor Pen in the application of optimising anti-psychotic drug intake. A pilot study has already shown very encouraging results.
The handwriting and symptoms in patients before and after taking anti-psychotic medication is being rated with the NeuroMotor Pen biomarkers to see if identifiable changes can help provide information about optimal dosage and assist with the monitoring of side effects.
Collaborators
















The NeuroMotor Pen can help improve the accuracy of early differential diagnosis by specialists in case of diagnostic uncertainty and help general practitioners to improve their referral accuracy and reduce unnecessary referrals to Parkinson's specialists.

Using the NeuroMotor Pen can offer a direct cost reduction for disease diagnosis as replacement for more expensive methods and assist with a timely, accurate diagnosis, that increases early treatment and avoids patient deterioration to the stage where intervention long-term care costs increase. The latter typically represents 70% of costs for Parkinson’s care.

Waiting list times for diagnosis and treatment can be reduced using the NeuroMotor Pen as less experienced clinicians and non-specialist healthcare workers can carry out initial tests to triage patients with suspected neuromotor impairments.
Make a difference today
Our disruptive technology has the potential to be used across many applications such as screening and triage, diagnosis, drug treatment optimisation, drug development, rehabilitation and research to improve our understanding of neuromotor impairments. We are keen to continue collaborating with interested researchers, clinicians and practitioners on our research in different areas, as well as businesses for further development and rolling out the existing and new products worldwide.